Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Retatrutide

GLP-1 / MetabolicResearch Use Only

Also known as: LY3437943, GGG tri-agonist, GIP/GLP-1/glucagon triple agonist

A triple-hormone (GLP-1 + GIP + glucagon) compound in late-stage trials — the strongest weight-loss signal yet published.

Dosing quick reference

research reference
Starting dose
2 mg once weekly
Frequency
Once weekly
Typical range
2–8 mg per week (advanced: 12)
Cycle
24+ weeks, stepping up every 4 weeks
Titration (step-up)
Wk 1–4: 2 → Wk 5–8: 4 → Wk 9–12: 6 → Wk 13+: 8 mg
Escalate by 2–4 mg every 4 weeks; never skip steps.
Half-life
~6 days
Route
Subcutaneous (research)
Common use
Metabolic and weight-management research
Common vial sizes
5 mg · 10 mg · 20 mg · 30 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
Referenced in research as a single triple-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetIncreased heart rate (reported in trials)
Regulatory note: Investigational; not FDA-approved and not approved in Canada. Phase 3 trials ongoing. Research-grade material is not for human use.
Calculate a dose →Retatrutide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.